What diseases does Secukinumab treat?

Secukinumab (Secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years of age and older who require systemic therapy or phototherapy. It is used to treat active psoriatic arthritis (PsA) in patients 2 years of age and older. It is also indicated for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adults with objective signs of inflammation and for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older. Secukinumab contains the active substance secukinumab. Before starting secukinumab, assess the patient's status for tuberculosis infection and complete all age-appropriate vaccinations as recommended by current immunization guidelines.

Secukinumab The original drug has been launched in China and has entered the scope of Class B medical insurance. However, domestic patients who can purchase this drug are limited to eligible patients with psoriasis and ankylosing spondylitis. Patients who are not eligible for medical insurance reimbursement can only purchase it at their own expense. The price of each box of 150mg/ML is about RMB 1,000. SecukinumabThe original drug has also been launched overseas. The specifications of the Turkish original versionThe price per box of 150mg/ML is about 1,500 yuan, and the European version is 150m. The price of each box of g/ML*2 is around RMB 15,000 (the price may fluctuate due to the exchange rate). The ingredients of foreign original drugs and domestic original drugs are basically the same. Currently, there are no generic secukinumab drugs on the market.